AI and the Pharmaceutical Industry — 2026-10-09 (Fri)

Glass blocks: a tall hazy stack, an outlined stack, and one solid stack, showing most headline AI pharma sums are unconfirmed while few are firm. — What this means, as an image (AI-generated, GPT Image): Investors must separate headline valuations and caps from committed money; only about $1.8B reads as firm.Download image (PNG, 2000×800)

Daily ReportPast 24h · aggregated 02:20 JST·12 items

A diagram for reading the amounts in 12 AI drug discovery headlines. The first stage sorts each sum into valuation, cap or plan. The second shows capital flowing in three directions: model-developer valuations, training-data preparation and joint labs with large players. The third narrows to what reads as firm, mainly the $1.8 billion from the US government and large Silicon Valley firms. What to watch: Isomorphic Labs' formal announcement and Iambic's IPO progress. — Image abstract — the whole article on one page (click to enlarge)

This section covers corporate investment behaviour of pharmaceutical companies, not the efficacy or safety of any medicinal product. Headlines are quoted as published; no claim about product performance is made or implied by this site. Collection and classification are automated and may misclassify or miss items. Disclaimer

Harvested 556Accepted 12Stale 103Duplicate 86Low-quality source 44Market noise 13Market research 6Off-topic 262No investment signal 25

💰 Investment MapAmounts are extracted from source text by pattern matching only. No currency conversion.

Amount	Deal	Function	Source
valuation $40B	Isomorphic Labs aims for $40B+ valuation in new funding, boosting AI drug discovery race.	🧬 Drug Discovery	Pluang
valuation 400億ドル	Google-backed AI drug discovery firm Isomorphic Labs reportedly seeking funding at a valuation of around $40 billion	🧬 Drug Discovery	BigGo ファイナンス
valuation 400億ドル	AI drug discovery firm Isomorphic in talks to raise funding at a corporate valuation of over $40 billion	🧬 Drug Discovery	Bloomberg.com
$1.8 Billion	U.S. Government and Silicon Valley Giants Pour $1.8 Billion into Closing the AI Drug Discovery Data Gap	🧬 Drug Discovery	BigGo Finance
$1.8B	Meta, Google, US Government Back $1.8B AI Biology Initiative: What It Means For Drug Discovery	🧬 Drug Discovery	Health and Me
18億ドル	US government teams up with major Silicon Valley firms to invest $1.8 billion to address data shortage in AI drug discovery	🧬 Drug Discovery	BigGo ファイナンス
up to $1 Billion	NVIDIA, Eli Lilly Plan Up to $1 Billion for AI Drug Lab	🏛️ Enterprise AI Platform & Governance	www.tokenpost.com
planned $150M	AI drug discovery startup Iambic seeks $150M in IPO	🧬 Drug Discovery	Axios
—	iM Securities Raises Hanmi Pharmaceutical Target to ₩650,000, Reflecting AI-Designed Obesity Drug Value	🏛️ Enterprise AI Platform & Governance	BigGo Finance
—	NVIDIA's 3-Year $X Investment in 14 AI Pharma Startups: Is a Wave of Star-Studded AI Pharmaceutical IPOs On the Horizon?	🏛️ Enterprise AI Platform & Governance	36Kr

The biggest development today is a report that Isomorphic Labs is seeking funding at a valuation of $40 billion or more.

Overview

The biggest development today is a report that Isomorphic Labs is seeking funding at a valuation of $40 billion or more. Separately, a $1.8 billion deal in which the US government and large Silicon Valley firms would address the data shortage in AI drug discovery has surfaced, so private valuation competition and public data-infrastructure building are moving in parallel. NVIDIA and Eli Lilly are planning an AI drug discovery lab of up to $1 billion, but that is a ceiling, not a confirmed amount.

By Category

In drug discovery, funding reports stand out. Isomorphic Labs is reportedly in talks at a valuation above $40 billion, and Iambic plans to raise $150M through an IPO. Neither has closed. In Japan, ITOCHU Corporation has entered a capital alliance with MOLCURE, promoting end-to-end support from candidate discovery through development. Almirall and Absci announced an AI drug discovery partnership.

In company-wide AI infrastructure and governance, the NVIDIA–Eli Lilly lab plan is the central item. There is a report that NVIDIA has invested in 14 AI drug discovery startups over three years, but the headline amount is masked as "$X," so the scale cannot be determined. On the operations side, JT's D-LAB has adopted "KIBIT Amanogawa," an AI tool for searching medical literature, and there are also moves into day-to-day R&D work, such as Seeq, Cognizant, and Simulations Plus on QSP model development.

Reading the Investment Map

The largest figure is Isomorphic Labs' $40 billion-plus, but this is a valuation, not an amount raised, and it comes from reports of talks and exploration. Next is the $1.8 billion going toward addressing the data shortage in AI drug discovery, from the US government and large Silicon Valley firms. The NVIDIA–Eli Lilly AI drug discovery lab is planned at up to $1 billion, a ceiling rather than a confirmed amount. Iambic's $150M is likewise an IPO plan or expectation. Capital is flowing in three directions: valuations of model-development companies, training-data preparation, and joint labs with large players that own compute infrastructure. Of today's headlines, the $1.8 billion is the main figure that can be read as a confirmed amount.

What to Watch

Whether Isomorphic Labs' funding is formally announced, and whether the valuation matches the reports. 2. Progress on Iambic's IPO filing, and any listing moves by other AI drug discovery companies NVIDIA has invested in.

🧬 Drug Discovery5